SCHEMBL2931427

SCHEMBL2931427

Clc1cccc(NCc2ccc(CN3CCOCC3)cc2)c1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 3/20 0.61
EPAS1 Q99814 3/20 0.61
KCNH2 Q12809 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.52
ALDH1A1 P00352 3/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
MEN1 O00255 1/20 0.52
PRKD3 O94806 1/20 0.52
HPGD P15428 1/20 0.52
KMT2A Q03164 1/20 0.52
PRKD1 Q15139 1/20 0.52
PRKD2 Q9BZL6 1/20 0.52
PDE4B Q07343 2/20 0.51
LMNA P02545 2/20 0.50
HRH3 Q9Y5N1 1/20 0.50
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2923321 0.89 CYP2A13 (0.61) HIF1AEPAS1KCNH2SMN1; SMN2ALDH1A1
SCHEMBL2926471 0.87 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1L3MBTL1LMNAHRH3
SCHEMBL4115394 0.79 SIGMAR1 (0.72) SMN1; SMN2ALDH1A1L3MBTL1MEN1HPGD
SCHEMBL2930005 0.78 SIGMAR1 (0.49) SMN1; SMN2ALDH1A1LMNA
SCHEMBL632349 0.77 EGFR (0.59) ALDH1A1MEN1HPGDKMT2ALMNA
SCHEMBL1964857 0.77 HDAC4 (0.54) SMN1; SMN2ALDH1A1L3MBTL1HPGDNPC1
Ammonia Solution, Strong SCHEMBL2931430 0.76 SIGMAR1 (0.58) SMN1; SMN2ALDH1A1L3MBTL1MEN1PRKD3
SCHEMBL631634 0.74 LMNA (0.59) SMN1; SMN2ALDH1A1MEN1HPGDKMT2A
4-(4-Chlorobenzyl)Morpholine SCHEMBL4103722 0.74 HRH3 (0.74) SMN1; SMN2ALDH1A1MEN1KMT2ALMNA
SCHEMBL15467001 0.73 HRH3 (0.87) HIF1AEPAS1SMN1; SMN2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121616-B1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS CAMPIANI GIUSEPPE (IT) 2010-09-15 EP disclosed
US-20100093726-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS GIUSEPPE CAMPIANI (IT) 2010-04-15 US disclosed
EP-2121616-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS Campiani, Giuseppe (IT) 2009-11-25 EP disclosed
WO-2008101891-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS CAMPIANI GIUSEPPE (IT) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093726-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS QTRT1, QTRT2, IL4I1 HIF1A 3412/4885EPAS1 2058/4885KCNH2 2280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.